29,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Interventions that reduce functional capacity — antipsychotics or benzodiazepines for agitation, activity restriction for fall prevention, prolonged bed rest, incontinence product use, and catheterization — remain common in nursing homes even though functional decline is measured, publicly reported, and built into Five-Star ratings. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia represents a substantial financial burden on society, one that is similar to the financial burden of heart disease and cancer. 3 key findings →
Design: longitudinal study Participants: 856 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The outcomes of each model of care differ and correspond to the model's focus. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Using a nationally representative survey of older Americans with in-home cognitive testing, researchers estimated that dementia cost the US between $157 billion and $215 billion in 2010, depending on how unpaid family caregiving time is valued. 4 key findings →
Design: cohort Participants: 856 Evidence: high
Full summary, score breakdown and related studies → Original source
The intervention provided that most scarce of caregiver commodities--time. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The results of this review highlight the significant economic burden of dementia for patients, families and healthcare systems and thus are important for future health policy planning. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Eighty six thousand three hundred ninety-six beneficiaries were included (43,198 beneficiaries with ADRD and 43,198 beneficiaries without ADRD). 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Nearly 40% of patients with dementia in our study experienced live discharge or a long length of stay. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Total monthly health care costs for individuals with ADRD are statistically greater (P<0.05) than controls beginning in the third month before diagnosis and remain significantly greater through the eighth month following diagnosis. 4 key findings →
Design: cohort study Participants: 927 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The results of the cost-effectiveness model presented here suggest that donepezil may be cost-effective but additional controlled data on long-term drug efficacy are needed. 5 key findings →
Design: cross-sectional Evidence: high
Full summary, score breakdown and related studies → Original source
Mean BBC in FY 2014 was 0.32; mean total cost in FY 2015 was $35 425. 4 key findings →
Participants: 102 Evidence: low
Full summary, score breakdown and related studies → Original source
We identified a cohort of 3619 incident dementia cases, 38.9% were male, and 66.9% were non-Hispanic White. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
BackgroundThere are 5.5 million people living with dementia in the United States (US), with the cost of unpaid care making up a significant portion of the care costs. 2 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Atrial fibrillation already accounts for a significant amount of National Health Service (NHS) funding, and over the coming years is highly likely to impose a growing cost on NHS budgets and the wider UK healthcare system. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Early-diagnosed patients (N = 421) have a lower utilization rate of inpatient skilled nursing facility, nursing home and hospitalization than late-diagnosed patients (N = 2817) after being diagnosed with AD. 5 key findings →
Design: case-control study Participants: 421 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among PWD with Medicaid, out-of-pocket costs for nursing homes and assisted living facilities were significantly higher (60%) compared to those TM (33%) and MA (30%). 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The rapid growth of the oldest age groups will have a major impact on future health care costs. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Policy makers in the US are increasingly concerned that greater use of the Medicare hospice benefit by people with dementia is driving up costs. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The main determinants of healthcare use in the Netherlands are old age and disabling conditions, particularly mental disability. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Finally, organizational characteristics (e.g., size and proprietary status) appear to be important enabling factors influencing the propensity to provide specialty care in dedicated units. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Data from the Canadian Study of Health and Aging (CSHA) were used to examine the relation between severity of Alzheimer's disease, as measured by the Mini-Mental State Examination (MMSE), and costs of caring. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Approximately 30% (4115 dollars) of the total annual cost of AD (14420 dollars) is invested in the direct management of BPSD. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Informal caregivers often seek additional support. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The objective of this prospective study was to evaluate the cost of Alzheimer disease (AD) in Israel. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Of 1648 patients with COVID-19 admitted to 38 hospitals, 398 (24.2%) died during hospitalization and 1250 (75.8%) survived. 5 key findings →
Design: systematic review Participants: 1,648 Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 29,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 29,780 records, built mostly from automated pulls of Europe PMC (63.8% of the library) and OpenAlex (17.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.5% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →